MMWR Morbidity and Mortality Weekly Report · 2021 · 127 citations · 7 references
Veterinary MedicineInfectious DiseasesPreventive MedicineEpidemiologyImmunizationVaccinologyClinical Vaccine TrialsMrna Vaccine TechnologyVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyCohort Study InvestigationComparative Clinical TrialsComparative Vaccine SafetyCovid-19 Vaccine HesitancyMortality Improvement RatesMortality RatesOverall Vaccine EffectivenessPopulation-based Vaccine Effectiveness
After standardizing mortality rates by age and sex, this study found that COVID-19 vaccine recipients had lower non-COVID-19 mortality than did unvaccinated persons. After adjusting for demographic characteristics and VSD site, this study found that adjusted relative risk (aRR) of non-COVID-19 mortality for the Pfizer-BioNTech vaccine was 0.41 (95% confidence interval [CI] = 0.38-0.44) after dose 1 and 0.34 (95% CI = 0.33-0.36) after dose 2. The aRRs of non-COVID-19 mortality for the Moderna vaccine were 0.34 (95% CI = 0.32-0.37) after dose 1 and 0.31 (95% CI = 0.30-0.33) after dose 2. The aRR after receipt of the Janssen vaccine was 0.54 (95% CI = 0.49-0.59). There is no increased risk for mortality among COVID-19 vaccine recipients. This finding reinforces the safety profile of currently approved COVID-19 vaccines in the United States.
7